Shreffler:Notebook/Staff Meetings/2011/03/15: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
Line 13: | Line 13: | ||
* EoE | * EoE | ||
** Early Risk factors (recruiting, nothing for lab) | ** Early Risk factors (recruiting, nothing for lab) | ||
** Biomarkers | ** Biomarkers (recruiting, n=12) | ||
*** EDN assays: SK will | *** EDN assays: will follow up with FL re: his experience; SK will tentatively plan to use assay with wider dynamic range | ||
*** | *** will not attempt to measure eotaxin from saliva at this time | ||
*** AM will | *** AM will order reagents for 16S cloning and plan in early April to pilot this with saliva pellet samples | ||
* Basophil | * Basophil | ||
** APC project | ** APC project | ||
*** SP showed data on DR kinetics by flow and | *** SP showed data on DR kinetics by flow comparing surface and intracellular expression at 20' and 18h from two donors -- one strongly responsive, one weakly | ||
***: DR increases over 18 hours in an IL-3 dependent fashion | ***: supports previous findings and the impression that strong responders upregulate expression of class II, where as weak responders do not | ||
***: DR increases in activation dep manner, but decreases from 20' to | ***: DR increases over 18 hours in an IL-3 dependent fashion -- saw this again | ||
***: | ***: DR increases in activation dep manner, but decreases from 20' to 18h | ||
***: One new observation was that in the case of the weak donor, activation dependent CD63 upregulation which was not present at 20' was prominent at 18 hours; this has implications for testing -- perhaps esp for activation by weak agonists (e.g. drugs) | |||
* Allergen Adjuvant | * Allergen Adjuvant | ||
** we | ** we do not expect to hear from proteonomics on new sequence information until end of month | ||
** | ** zymosan experiment (n=1) shows lack of ALDH1A2 induction by zymosan, strong induction by fraction 3 -- lacks positive control target for zymosan (e.g. IL-10) to determine whether iDC are unresponsive to zymosan generally, or simply this pathway is not stimulated | ||
* PM Baso | * PM Baso | ||
** AM | ** AM repeated the anergy experiment, including a 90' rest between stim 1 and 2. Clear desensitization, but some 'carryover', specifically with Derp2 stim conditions (perhaps higher affinity) | ||
**: | **: SP notes that we cannot distinguish in these experiments between insufficient suppression of degran in Ca free conditions versus delayed degranulation occurring upon shift into Ca | ||
* JAX | * JAX | ||
** updated scripts for JAX to run as data comes in | ** updated scripts for JAX to run as data comes in | ||
'''**: Note nec format for pcr data needs to be reviewed with AM''' | |||
** AM to catch up on analysis this month | ** AM to catch up on analysis this month | ||
** requesting that K at Hopkins adds comment column for lab notes | ** requesting that K at Hopkins adds comment column for lab notes (status?) | ||
* PM baso | * PM baso | ||
** AM to finish analysis | ** AM to finish analysis during AAAAI | ||
* Carboplatin | * Carboplatin | ||
Line 48: | Line 49: | ||
* U19 | * U19 | ||
** BR to | ** BR to review protocol and plans to begin long term cultures, contact Dutch group | ||
**: will have follow up meeting with JM in ~2 months | |||
Revision as of 09:27, 15 March 2011
ShreffLab Staff Meetings | <html><img src="/images/9/94/Report.png" border="0" /></html> Main project page <html><img src="/images/c/c3/Resultset_previous.png" border="0" /></html>Previous entry<html> </html> |
15 March 2011Agenda Items
**: Note nec format for pcr data needs to be reviewed with AM
|